{"entity":{"id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-4375 Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07298772 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 198 participants planned, started 2026-01-07 and due to reach its primary completion in 2027-01. Interventions recorded: SHR-4375 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07298772","url":"https://clinicaltrials.gov/study/NCT07298772"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07298772","phase":"1/2","setting":"A Phase Ib/II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":198,"outcomes":[]},"route":"/trials/nct07298772/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}